Non-contrast spectral CT for differentiating hepatic hemangioma from hepatocellular carcinoma in chronic liver disease

Purpose To evaluate quantitative non-contrast dual-layer detector spectral CT (DLCT) for differentiating hepatic hemangioma (HH) from hepatocellular carcinoma (HCC) in chronic liver disease (CLD). Methods This retrospective study included 90 patients with CLD and 92 focal liver lesions (35 HHs, 57 HCCs) who underwent non-contrast and multiphase contrast-enhanced DLCT between September 2023 and April 2026. Diagnoses were established by pathology or typical CT/MRI findings with clinical follow-up. Clinical variables and DLCT parameters, including virtual monoenergetic CT attenuation, spectral attenuation curve slopes, effective atomic number (Zeff), and electron density (ED), were assessed. Clinical, DLCT, and combined logistic regression models were evaluated using repeated nested cross-validation. Results Compared with HHs, HCCs were associated with older age, more frequent cirrhosis and alpha-fetoprotein positivity, larger maximum lesion diameter, and more frequent abnormal albumin and total bilirubin levels (all p < 0.05). HU40, λHU40–100, and Zeff were higher in HCCs, whereas HU100, HU140, and ED were lower (all p < 0.05). Alpha-fetoprotein, maximum lesion diameter, Zeff, and ED were independent predictors. In outer cross-validation, the combined model showed the highest performance (AUC, 0.814; 95% CI, 0.806–0.823), with sensitivity, specificity, and accuracy of 0.723, 0.761, and 0.738. It outperformed the clinical and DLCT models (both p < 0.001) and improved reclassification over both. Conclusion Non-contrast DLCT parameters, particularly Zeff and ED, help differentiate HH from HCC in CLD. Their combination with clinical variables improved discrimination and risk reclassification.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1967307
Primary Topic
Advanced X-ray and CT Imaging
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Non-contrast spectral CT for differentiating hepatic hemangioma from hepatocellular carcinoma in chronic liver disease

Tao Ren, Yangsen Liu, Yunhang Jing, Qinghong Yan et al.
2 links
Frontiers in Oncology
Advanced X-ray and CT Imaging
article

Non-contrast spectral CT for differentiating hepatic hemangioma from hepatocellular carcinoma in chronic liver disease

Tao Ren, Yangsen Liu, Yunhang Jing, Qinghong Yan, Mengyuan Hao, Xingyue Xu, Yihan Liu
article en

Abstract

Purpose To evaluate quantitative non-contrast dual-layer detector spectral CT (DLCT) for differentiating hepatic hemangioma (HH) from hepatocellular carcinoma (HCC) in chronic liver disease (CLD). Methods This retrospective study included 90 patients with CLD and 92 focal liver lesions (35 HHs, 57 HCCs) who underwent non-contrast and multiphase contrast-enhanced DLCT between September 2023 and April 2026. Diagnoses were established by pathology or typical CT/MRI findings with clinical follow-up. Clinical variables and DLCT parameters, including virtual monoenergetic CT attenuation, spectral attenuation curve slopes, effective atomic number (Zeff), and electron density (ED), were assessed. Clinical, DLCT, and combined logistic regression models were evaluated using repeated nested cross-validation. Results Compared with HHs, HCCs were associated with older age, more frequent cirrhosis and alpha-fetoprotein positivity, larger maximum lesion diameter, and more frequent abnormal albumin and total bilirubin levels (all p < 0.05). HU40, λHU40–100, and Zeff were higher in HCCs, whereas HU100, HU140, and ED were lower (all p < 0.05). Alpha-fetoprotein, maximum lesion diameter, Zeff, and ED were independent predictors. In outer cross-validation, the combined model showed the highest performance (AUC, 0.814; 95% CI, 0.806–0.823), with sensitivity, specificity, and accuracy of 0.723, 0.761, and 0.738. It outperformed the clinical and DLCT models (both p < 0.001) and improved reclassification over both. Conclusion Non-contrast DLCT parameters, particularly Zeff and ED, help differentiate HH from HCC in CLD. Their combination with clinical variables improved discrimination and risk reclassification.

Frontiers in OncologyVol. 16
Yanan University Affiliated Hospital (CN), Yan'an University (CN), Lanzhou University Second Hospital (CN)
Good health and well-being
Advanced X-ray and CT Imaging
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon